




## Cycloserine LCMS Separation of Impurities and Degradants - AppNote

### LCMS Separation of Impurities and Degradants

While two major impurities observed in this Cycloserine method were not directly identified, several possibilities can be suggested based on their  $m/z$  values in the Mass Spectrum and their relationship to the Serine structure. Serine was also identified but in very low abundance and only after the samples were several weeks old.

This study did not involve the development of a fully validated method; however a linear relationship following the equation  $2E+6x - 280000$  was obtained for the determination of Cycloserine over the concentration range of 0.2–1.0  $\mu\text{g} / \text{mL}$  having an  $R^2$  value of 0.993. The limit of detection is estimated to be 0.1  $\mu\text{g} / \text{mL}$ . The repeatability of the method, both inter and intra-day, is good.





### Peak:

1. Unknown at  $m/z$  285
2. Unknown at  $m/z$  245
3. Cycloserine dimer at  $m/z$  205.0931
4. Cycloserine at  $m/z$  103.0502 (*Fig. A*)
5. Serine at  $m/z$  106.0499 (*Fig. B*)

## Method Conditions

**Column:** Cogent Diamond Hydride™, 4 $\mu$ m, 100Å

**Catalog No.:** [70000-15P-2](#)

**Dimensions:** 2.1 x 150mm

**Mobile Phase:**

A: DI Water / 0.1% Formic Acid (v/v)

B: Acetonitrile / 0.1% Formic Acid (v/v)

**Gradient:**

Time (minutes)	%B
0	70
2	20
6	20
7	70

**Post Time:** 2 minutes

**Flow rate:** 0.4 mL / minute

**Detection:** ESI – POS – Agilent 6210 MSD TOF Mass Spectrometer

**Injection vol.:** 1 $\mu$ L

**Sample Preparation:** Stock solutions of the analytes were made in DI Water in the range of 0.2–0.7

mg / mL. All samples were filtered through a disposable 0.45µm Syringe Filter (MICROSOLV Tech Corp.). Samples for injection were diluted 1:10 with 50:50 Solvent A:B mixture.

**t<sub>0</sub>**: 0.9 minutes

**Note:** *Until recently, Cycloserine has not been in wide-spread use for the treatment of tuberculosis due to its toxicity. With more drug-resistant strains of TB emerging, Cycloserine treatment is becoming more common.*



## Attachment

**No 168 Cycloserine pdf** 0.3 Mb [Download File](#)

Printed from the Chrom Resource Center

Copyright 2025, All Rights Apply

**MicroSolv Technology Corporation**

9158 Industrial Blvd. NE, Leland, NC 28451

Tel: (732) 380-8900

Fax: (910) 769-9435

Email: [customers@mtc-usa.com](mailto:customers@mtc-usa.com)

Website: [www.mtc-usa.com](http://www.mtc-usa.com)